ADGI Stock Price, Adagio Therapeutics, . Quote, Chart

Market Summary

USD2.13-0.14

Market Closed

-6.17%

ADGI Stock Price

View Fullscreen

ADGI RSI Chart

ADGI Valuation

Market Cap

253.9M

Price/Earnings (Trailing)

-1.28

Price/Free Cashflow

-1.46

ADGI Price/Earnings (Trailing)

ADGI Profitability

Return on Equity

-111.93%

Return on Assets

-86.68%

Free Cashflow Yield

-68.43%

ADGI Fundamentals

ADGI Earnings

Earnings (TTM)

-198.6M

Earnings Growth (Yr)

-65.24%

Earnings Growth (Qtr)

-86.75%

Breaking Down ADGI Revenue

Last 7 days

-14.1%

Last 30 days

-34.5%

Last 90 days

-52.1%

How does ADGI drawdown profile look like?

ADGI Financial Health

Current Ratio

4.47

ADGI Investor Care

Shares Dilution (1Y)

1.02%

Diluted EPS (TTM)

-1.81

Tracking the Latest Insider Buys and Sells of Adagio Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 01, 2022	hering david	bought	36,160	4.52	8,000	chief executive officer
Aug 19, 2022	elia marc	bought	2,700,160	4.62	584,451	-
Aug 18, 2022	elia marc	bought	5,454,520	4.31	1,265,550	-
Aug 17, 2022	elia marc	bought	4,040,000	4.04	1,000,000	-
Mar 03, 2022	adimab, llc	sold	-	-	-1,158,090	-
Aug 10, 2021	mcguire terrance	bought	8,500,000	17.00	500,000	-
Aug 10, 2021	mcguire terrance	acquired	-	-	8,031,700	-
Aug 10, 2021	redmile group, llc	bought	24,990,000	17.00	1,470,000	-
Aug 10, 2021	redmile group, llc	acquired	-	-	1,920,960	-
Aug 10, 2021	adimab, llc	acquired	-	-	25,860,700	-

Which funds bought or sold ADGI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	new	-	4,380	4,380	-%
Apr 18, 2024	Aspire Private Capital, LLC	unchanged	-	100	888	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.99	5,672,680	9,904,000	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	371	387,583	426,600	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	520	709,567	762,619	-%
Feb 15, 2024	Farther Finance Advisors, LLC	new	-	4.00	4.00	-%
Feb 15, 2024	BARCLAYS PLC	new	-	285,000	285,000	-%
Feb 14, 2024	MAVERICK CAPITAL LTD	added	77.29	27,855,700	36,815,200	0.74%
Feb 14, 2024	DEUTSCHE BANK AG\	sold off	-100	-5,029	-	-%
Feb 14, 2024	STATE STREET CORP	reduced	-0.51	391,046	690,513	-%

Are Funds Buying or Selling ADGI?

Are funds buying ADGI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADGI

No. of Funds

Unveiling Adagio Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	maverick capital ltd	8.5%	9,343,949	SC 13G
Feb 12, 2024	deep track capital, lp	7.56%	9e+06	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 22, 2024	adimab, llc	19.7%	21,687,906	SC 13D/A
Sep 11, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Aug 19, 2022	m28 capital management lp	8.50%	9,248,250	SC 13D/A
Jul 05, 2022	mithril ii lp	10.2%	11,241,580	SC 13D/A
Jun 24, 2022	population health equity partners iii, l.p.	33%	359,662	SC 13D/A
Jun 24, 2022	m28 capital management lp	5.78%	6,398,250	SC 13D/A

Recent SEC filings of Adagio Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	EFFECT	EFFECT
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 12, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 12, 2024	SC 13G	Major Ownership Report

Adagio Therapeutics, Inc. News

Latest updates

Adagio Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-16.6%	229	275	315	351	383	425	485	556	620	686	398	117
Current Assets	-16.7%	225	270	310	345	377	422	481	554	617	680	396	117
Cash Equivalents	10.4%	201	182	122	126	92.00	278	475	532	542	478	393	115
Net PPE	-5.3%	2.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	-	-	-
Liabilities	82.0%	52.00	28.00	34.00	24.00	27.00	47.00	70.00	97.00	62.00	53.00	38.00	13.00
Current Liabilities	87.7%	50.00	27.00	33.00	22.00	25.00	46.00	68.00	96.00	62.00	53.00	38.00	13.00
Shareholder's Equity	-28.0%	177	246	282	327	356	377	415	459	558	633	-	-
Retained Earnings	-11.2%	-732	-658	-618	-568	-533	-488	-443	-392	-292	-209	-148	-65.32
Additional Paid-In Capital	0.5%	910	905	901	896	890	866	859	852	850	842	4.00	0.00
Shares Outstanding	0.3%	110	110	110	109	109	108	108	108	111	20.00	6.00	6.00
Float	-	-	-	67.00	-	-	-	229	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-67.6%	-59,240	-35,352	-37,391	-41,181	-47,404	-56,142	-57,392	-59,049	-73,212	-54,213	-33,570	-23,741	-13,428	-1,143
Share Based Compensation	1.9%	4,344	4,264	4,677	5,400	5,905	7,399	6,361	1,983	7,856	5,979	3,342	587	148	7.00
Cashflow From Investing	-18.1%	77,918	95,135	32,595	75,036	-138,813	-140,837	-17.00	49,000	137,916	-188,627	-	-	-	-
Cashflow From Financing	53.3%	141	92.00	270	542	141	246	74.00	45.00	-749	328,600	334,832	-	79,839	49,720
Buy Backs	-	-	-	1.00	-	-	-	2.00	2.00	-	-	-	-	-82.00	85.00

ADGI Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Operating expenses:

Research and development

^[1]

$ 158,658

$ 179,214

Acquired in-process research and development

^[2]

4,975

4,400

Selling, general and administrative

49,125

47,044

Warrant expense

^[3]

0

17,373

Total operating expenses

212,758

248,031

Loss from operations

(212,758)

(248,031)

Other income:

Other income, net

14,115

6,714

Total other income, net

14,115

6,714

Net loss

(198,643)

(241,317)

Other comprehensive income (loss)

Unrealized gain (loss) on available-for-sale securities, net of tax

259

(264)

Comprehensive loss

$ (198,384)

$ (241,581)

Net loss per share attributable to common stockholders, basic

$ (1.81)

$ (2.23)

Net loss per share attributable to common stockholders, diluted

$ (1.81)

$ (2.23)

Weighted-average common shares outstanding, diluted

109,526,053

108,268,289

Weighted-average common shares outstanding, basic

109,526,053

108,268,289

[1]	Includes related-party amounts of $8,418 and $8,154 for the years ended December 31, 2023 and 2022, respectively (see Note 15).
[2]	Includes related-party amounts of $4,975 and $4,400 for the years ended December 31, 2023 and 2022, respectively (see Note 15).
[3]	Includes related-party amounts of $0 and $17,373 for the years ended December 31, 2023 and 2022, respectively (see Note 15).

ADGI Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 200,641	$ 92,076
Marketable securities	0	279,915
Prepaid expenses and other current assets	24,240	4,926
Total current assets	224,881	376,917
Property and equipment, net	1,896	2,282
Operating lease right-of-use asset	2,229	3,777
Other non-current assets	175	191
Total assets	229,181	383,167
Current liabilities:
Accounts payable	7,953	1,517
Accrued expenses	40,860	21,911
Operating lease liabilities, current	1,443	1,559
Other current liability	35	44
Total current liability	50,291	25,031
Operating lease liabilities, non-current	722	2,165
Other non-current liability	700	0
Early-exercise liability	0	1
Total liabilities	51,713	27,197
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 110,160,684 shares issued and outstanding at December 31, 2023; 109,044,046 shares issued and outstanding at December 31, 2022	11	11
Additional paid-in capital	909,539	889,657
Accumulated other comprehensive loss	(13)	(272)
Accumulated deficit	(732,069)	(533,426)
Total stockholders' equity	177,468	355,970
Total liabilities, preferred stock and stockholders' equity	$ 229,181	$ 383,167

About Adagio Therapeutics, Inc.

0

WEBSITE	https://adagiotx.com

Adagio Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Adagio Therapeutics, Inc.? What does ADGI stand for in stocks?

ADGI is the stock ticker symbol of Adagio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adagio Therapeutics, Inc. (ADGI)?

As of Wed Apr 24 2024, market cap of Adagio Therapeutics, Inc. is 253.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADGI stock?

You can check ADGI's fair value in chart for subscribers.

What is the fair value of ADGI stock?

You can check ADGI's fair value in chart for subscribers. The fair value of Adagio Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adagio Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADGI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adagio Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ADGI is over valued or under valued. Whether Adagio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Adagio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADGI.